-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a German team published a study in the journal BMC Cancer, mainly to study the hematological changes of durvalumab maintenance therapy after concurrent chemoradiotherapy (cCRT) in patients with stage III unresectable NSCLC
.
.
NSCLC
The study included 22 patients who completed platinum-based cCRT followed by durvalumab maintenance therapy
.
Analysis of parameters such as hemoglobin (Hb), leukocytes, lactate dehydrogenase (LDH), C-reactive protein (CRP), body weight, albumin before cCRT, after cCRT, and after starting durvalumab for 3, 6, 9, and 12 months changes
The study included 22 patients who completed platinum-based cCRT followed by durvalumab maintenance therapy
Of the 22 patients, 16 (72.
During maintenance therapy, mean hemoglobin (Hb) increased by 1.
Compared to initiation of durvalumab, LDH decreased by 29.
86 U/l (11.
74%) after 3 months (p = 0.
022) and mean LDH decreased by 8.
75 U/l (3.
43%; p = 0.
34) at 6 months, 9 It decreased by 11.
95 U/l (4.
76%) after one month (p = 0.
26)
.
At the end of the 12-month observation period, mean LDH decreased by 36.
Compared to initiation of durvalumab, LDH decreased by 29.
CRP > 5 mg/dl was defined as CRP elevation based on all values measured in the group
.
CRP was elevated in 1 patient (4.
CRP > 5 mg/dl was defined as CRP elevation based on all values measured in the group
Median weight change [kg] after 12 months was +6.
06% (range: 8.
89 +18.
75%)
.
Durvalumab cycles were significantly associated with total body weight gain [kg] (spearma-Rho correlation: r = 0.
Median weight change [kg] after 12 months was +6.
There were no significant changes in liver and kidney function
.
.
In conclusion, the study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, no serious hematological toxicity was observed in laboratory blood tests
.
Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
.
.
Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
.
The study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, laboratory blood tests showed no serious hematologic toxicity
.
Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
.
The study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, laboratory blood tests showed no serious hematologic toxicity
.
Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
.
Original source:
Original source:J.
Guggenberger, S.
Kenndof, J.
Taugner, et al.
Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
BMC Cancer (2022) 22:317.
https: https://doi.
org/10.
1186/s12885-022-09395-6
Guggenberger, S.
Kenndof, J.
Taugner, et al.
Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
BMC Cancer (2022) 22:317.
https: https://doi.
org/10.
1186/s12885-022-09395-6
leave a message here